Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)

Phase 3

• Conditions: RA

• Registration Number: JPRN-jRCT2080220018
• Lead Sponsor: Chugai Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion criteria
(1) Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR)
(2) Between 20 and 75 years old

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy: Frequency of ACR improvement Safety: Frequency and severity of adverse events and adverse drug reactions